RETRANSMISSION: Shuttle Pharmaceuticals Launches Autonomous Self Reasoning AI Agent for Scientific Workflows

Gaithersburg, Maryland--(Newsfile Corp. - March 27, 2026) - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) ("Shuttle Pharma" or the "Company"), today announced a major advancement to its molecule.ai platform, significantly expanding its capabilities in therapeutic discovery and positioning the Company at the forefront of AI-driven drug development.

The latest release introduces new models that enable users to more effectively evaluate, prioritize, and advance therapeutic candidates. By integrating enhanced predictive and generative capabilities into a unified platform, Shuttle Pharma is accelerating the transition from fragmented data analysis toward a scalable, end-to-end solution for therapeutic development.

This update marks a critical evolution for AI-driven drug discovery: from standalone model outputs to a more sophisticated reasoning system. The platform can now identify and prioritize relationships between genes and disease pathways and predict compound interactions with specific biological targets. Combined with existing molecular prediction tools, molecule.ai delivers a more connected and efficient framework for evaluating therapeutic opportunities—driving faster, higher-confidence decision-making earlier in the discovery lifecycle.

In addition, the Company unveiled a preview of its next-generation autonomous AI agent system, built on top of frontier AI models. This system is designed to move beyond traditional single-step predictions by enabling multi-step reasoning and multi-agent orchestration across complex scientific workflows. The agents will be capable of ingesting multimodal data, leveraging integrated tools, and executing discrete research tasks—dramatically reducing manual effort and increasing throughput for research teams.

"This release represents a meaningful step toward fully autonomous therapeutic discovery," said Chris Cooper, Chief Executive Officer of Shuttle Pharma. "We are not just improving model performance—we are redefining how drug development workflows are executed. By integrating reasoning, prediction, and automation into a single platform, molecule.ai has the potential to materially reduce timelines, lower costs, and increase the probability of success across the development pipeline. We believe this positions Shuttle Pharma to play a leading role in the next generation of AI-powered biopharma innovation."